 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Applied Therapeutics to present data from study of caficrestat in DbCM

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...

Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024

Applied Therapeutics, Inc. (NASDAQ:APLT - Get Free Report) was the target of a significant decline in short interest in March. As of March 15th, there was short interest totalling 3,790,000 shares...

Applied Therapeutics, Inc. (NASDAQ:APLT) Short Interest Down 12.5% in March

U.S. stock futures were higher this morning, with the Dow futures gaining by over 100 points on Monday.
read more...

Oxford Industries Posts Weak Results, Joins Applied Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Royal Bank of Canada assumed coverage on shares of Applied Therapeutics (NASDAQ:APLT  Free Report) in a research note issued to investors on Tuesday, Marketbeat.com reports. The brokerage...

Applied Therapeutics (NASDAQ:APLT) Earns Outperform Rating from Analysts at Royal Bank of Canada

Applied Therapeutics gets extension of FDA review for rare disease drug...

Applied Therapeutics gets extension of FDA review for rare disease drug

Applied Therapeutics down 11% after extended FDA review for govorestat NDA

Applied Therapeutics: FDA extends review period for NDA for govorestat

NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...

Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia

This indicator may be signaling APLT's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

Applied Therapeutics (APLT, $6.75) entered Uptrend as Momentum indicator ascends above 0 level on Mar 25, 2024

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. It is targeting treatments for central nervous system rare diseases and diabetic complications. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.

Volume (M)	724,676.00
52-Wk High	$9.39
52-Wk Low	$0.9283

APLT Applied Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals